2014 NCCN Congress Series™: Utilizing Guidelines to Customize Patient Care in NSCLC - Treatment of Advanced Disease
Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer. The 2014 NCCN Congress Series™: Utilizing Guidelines to Customize Patient Care in Non-Small Cell Lung Cancer will discuss the most recent developments in diagnosis and treatment to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with non-small cell lung cancer.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with non-small cell lung cancer.
Following this activity, participants should be able to:
- Explain the most appropriate first-line, maintenance, second-line, and third-line therapies in patients with lung cancer, including those with specific driver mutations
- Describe the factors related to the selection of maintenance therapy for lung cancer patients
- Indicate the optimal therapeutic management of patients with sensitizing EGFR mutations and ALK gene rearrangements
Jyoti D. Patel, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician